A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is application/pdf
.
Cixutumumab-Associated Pancolitis in a Patient With Prostate Cancer
2013
Clinical Genitourinary Cancer
Introduction New therapies for cancer have emerged as we have gained better understanding of the molecular mechanisms that underlie those diseases. Several types of tumors, including prostate cancer (PC), overexpress the insulin-like growth factor 1 receptor (IGF1R). 1 The antitumor effect of IGF1R inhibition has been noted in both in vitro and in vivo models of PC. 2,3 Several different agents, including such monoclonal antibodies as IMC-A12 (cixutumumab), have been developed as antagonists to
doi:10.1016/j.clgc.2012.09.009
pmid:23083799
pmcid:PMC3579009
fatcat:2gvz656zhbacfdvu52xgfkmziu